

# Cristina Bianchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8521414/publications.pdf>

Version: 2024-02-01

72  
papers

1,969  
citations

257101

24  
h-index

264894

42  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3321  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	5.5	231
2	Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 250-254.	1.1	161
3	Review of methods for detecting glycemic disorders. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108233.	1.1	108
4	Exenatide: a review from pharmacology to clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 544-556.	2.2	96
5	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired $\beta$ -Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2100-2105.	1.8	92
6	Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 2-17.	1.1	81
7	$\beta$ -Cell function and anti-diabetic pharmacotherapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 518-527.	1.7	68
8	Treating the metabolic syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 491-506.	0.6	53
9	Metabolic Memory and Individual Treatment Aims in Type 2 Diabetes " Outcome-Lessons Learned from Large Clinical Trials. <i>Review of Diabetic Studies</i> , 2011, 8, 432-440.	0.5	50
10	Left Ventricular Function in Normotensive Young Adults With Well-Controlled Type 1 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 84-90.	0.7	45
11	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 997-1006.	1.1	42
12	The role of adipokines in the pathogenesis of gestational diabetes mellitus. <i>Gynecological Endocrinology</i> , 2019, 35, 737-751.	0.7	42
13	Primary Prevention of Cardiovascular Disease in People With Dysglycemia. <i>Diabetes Care</i> , 2008, 31, S208-S214.	4.3	40
14	Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?. <i>Current Diabetes Reports</i> , 2013, 13, 403-410.	1.7	39
15	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. <i>Diabetologia</i> , 2017, 60, 1102-1113.	2.9	38
16	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. <i>European Journal of Nutrition</i> , 2018, 57, 679-688.	1.8	38
17	Type 1 diabetes and COVID-19: The "lockdown effect". <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108468.	1.1	37
18	Pathogenetic Mechanisms and Cardiovascular Risk. <i>Diabetes Care</i> , 2012, 35, 2607-2612.	4.3	36

#	ARTICLE	IF	CITATIONS
19	Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin. <i>Atherosclerosis</i> , 2008, 197, 346-354.	0.4	35
20	Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes?. <i>Diabetes Research and Clinical Practice</i> , 2018, 144, 286-293.	1.1	33
21	Metabolic regulation of GLP-1 and PC1/3 in pancreatic $\beta$ -cell line. <i>PLoS ONE</i> , 2017, 12, e0187836.	1.1	31
22	Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108750.	1.1	28
23	Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. <i>Diabetes Care</i> , 2009, 32, S342-S348.	4.3	27
24	Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 246-253.	1.1	25
25	Optimizing management of metabolic syndrome to reduce risk: focus on life-style. <i>Internal and Emergency Medicine</i> , 2008, 3, 87-98.	1.0	25
26	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 247-264.	4.9	25
27	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , 2021, 44, 1062-1069.	4.3	25
28	Prescribing exercise for prevention and treatment of gestational diabetes: review of suggested recommendations. <i>Gynecological Endocrinology</i> , 2017, 33, 254-260.	0.7	23
29	The metabolic syndrome is related to albuminuria in Type 2 diabetes. <i>Diabetic Medicine</i> , 2008, 25, 1412-1418.	1.2	22
30	Glucose-Related Arterial Stiffness and Carotid Artery Remodeling: A Study in Normal Subjects and Type 2 Diabetes Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2362-E2366.	1.8	21
31	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108112.	1.1	21
32	Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 6-12.	1.2	20
33	Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 31-38.	1.1	17
34	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154242.	1.5	17
35	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 699-705.	1.1	16
36	Early vs. standard screening and treatment of gestational diabetes in high-risk women – An attempt to determine relative advantages and disadvantages. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 598-603.	1.1	16

#	ARTICLE	IF	CITATIONS
37	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. <i>Nature Communications</i> , 2022, 13, 684.	5.8	16
38	Hyperglycaemia and cardiovascular risk. <i>Acta Diabetologica</i> , 2003, 40, s362-s369.	1.2	15
39	Access to emergency room for hypoglycaemia in people with diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 745-751.	1.7	15
40	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1160-E1167.	1.8	15
41	Effects of treatment with metformin and/or sitagliptin on beta cell function and insulin resistance in prediabetic women with previous gestational diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 648-657.	2.2	15
42	Pharmacological intervention in prediabetes: considering the risks and benefits. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 17-22.	2.2	13
43	Insulin resistance and lipid disorders. <i>Future Lipidology</i> , 2008, 3, 651-664.	0.5	13
44	Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2014, 10, 465.	1.0	13
45	Personalized Therapy by Phenotype and Genotype. <i>Diabetes Care</i> , 2016, 39, S127-S136.	4.3	13
46	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> , 2020, 43, e139-e141.	4.3	13
47	Early detection of left ventricular dysfunction in diabetes mellitus patients with normal ejection fraction, stratified by BMI: A preliminary speckle tracking echocardiography study. <i>Journal of Cardiovascular Echography</i> , 2013, 23, 73.	0.1	12
48	Italian national guidelines for the screening of gestational diabetes: Time for a critical appraisal?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 717-722.	1.1	11
49	Postpartum screening for type 2 diabetes mellitus in women with gestational diabetes: Is it really performed?. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108309.	1.1	9
50	Risk factors associated with postpartum impaired glucose regulation in women with previous gestational diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107854.	1.2	9
51	Glomerular filtration rate: A prognostic marker in atrial fibrillation? A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. <i>Clinical Cardiology</i> , 2018, 41, 1570-1577.	0.7	8
52	Blood Glucose Control and Coronary Heart Disease. <i>Herz</i> , 2010, 35, 148-159.	0.4	7
53	Use of non-nutritive-sweetened soft drink and risk of gestational diabetes. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108943.	1.1	7
54	Serum gamma-glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 181-186.	1.7	5

#	ARTICLE	IF	CITATIONS
55	How much weight are women gaining during pregnancy? An Italian cohort study. <i>Gynecological Endocrinology</i> , 2015, 31, 942-944.	0.7	5
56	Exercise during pregnancy: how much active are pregnant women at risk of gestational diabetes despite few contraindications?. <i>Gynecological Endocrinology</i> , 2021, 37, 101-104.	0.7	5
57	Insulin as an Early Treatment for Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, S198-S204.	4.3	4
58	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance.. <i>Diabetes and Metabolism</i> , 2022, 48, 101292.	1.4	4
59	Insulin secretion and action affect glucose variability in the early stages of glucose intolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3531.	1.7	4
60	Serum gamma-glutamyltransferase is not associated to peripheral arterial disease in type 2 diabetic patients: Cross-sectional findings. <i>Atherosclerosis</i> , 2009, 203, 49-50.	0.4	2
61	Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. <i>Diabetologia</i> , 2017, 60, 2123-2125.	2.9	2
62	Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. <i>BMC Nephrology</i> , 2018, 19, 347.	0.8	2
63	Common Variants Associated to Type 2 Diabetes in the Italian Population. <i>Open Journal of Endocrine and Metabolic Diseases</i> , 2021, 11, 24-42.	0.2	1
64	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> 2020;43:e139â€“e141. <i>Diabetes Care</i> , 2021, 44, e81-e81.	4.3	1
65	920-P: Flash Glucose Monitoring (FGM) in Real-Life: 18-Month Clinical Experience. <i>Diabetes</i> , 2019, 68, 920-P.	0.3	1
66	1392-P: Assisted Reproduction Technology Treatment and Risk of Gestational Diabetes. <i>Diabetes</i> , 2020, 69, 1392-P.	0.3	1
67	Prognostic implications of diabetes phenotyping: new concepts for an old disease. <i>Internal and Emergency Medicine</i> , 2009, 4, 325-329.	1.0	0
68	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
69	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0
70	921-P: Managing Trend Arrows with FGM: Effects on Glycemic Control in Type 1 Diabetic (T1DM) Subjects. <i>Diabetes</i> , 2019, 68, .	0.3	0
71	65-OR: Effects of Treatment with Metformin and/or Sitagliptin on Beta-Cell Function and Insulin Resistance in Prediabetic Women with Previous Gestational Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	0
72	515-P: Nonalbuminuric Diabetic Kidney Disease in Type 1 Diabetes: Incidence of Major Vascular Outcomes over a 10-Year Follow-Up. <i>Diabetes</i> , 2020, 69, .	0.3	0